Novo Holdings

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

Kate Farms, Inc. specializes in the production of plant-based meal replacement shakes and tube feeding solutions, catering to individuals with various dietary and medical needs. Established in 2011 and headquartered in Santa Barbara, California, with an additional office in Waltham, Massachusetts, the company has become a leader in vegan nutrition. Its enteral formulas are designed for easy digestion and are free from common allergens such as dairy, soy, and gluten, making them suitable for a wide range of patients. Clinicians have reported positive outcomes, including reduced gastrointestinal intolerance and improved nutritional status for users. By combining advanced scientific research with natural ingredients, Kate Farms aims to enhance health and well-being, empowering caregivers, healthcare professionals, and patients to choose effective nutritional solutions. The company's commitment to quality ensures that everyone has access to nourishing options that promote overall health.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

BioMason is a biotechnology start-up focused on the building and construction industry, founded in 2012 and headquartered in Research Triangle Park, North Carolina. The company specializes in the production of biological cement-based masonry materials using natural microorganisms and chemical processes. Its product offerings include concrete masonry tiles suitable for various applications, biocement for dust control, and solutions for soil stabilization. BioMason aims to innovate the construction sector by providing sustainable alternatives that reduce environmental impact and enhance the efficiency of building practices.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Doctor Anywhere Pte Ltd is a Singapore-based telehealth company that provides an online platform for health and wellness solutions. Established in 2016, the company specializes in video consultations, allowing patients to consult with licensed and registered doctors for various medical needs. Its digital platform offers on-demand healthcare services that are designed to be simple, seamless, and convenient, catering to the evolving lifestyle preferences of users. By integrating a range of health services, Doctor Anywhere enables patients to receive appropriate diagnoses, medication, and e-prescriptions, facilitating access to healthcare anytime and anywhere. The company aims to improve health outcomes through technology, addressing modern healthcare challenges and enhancing the overall patient experience.

Genomatica, Inc. specializes in developing innovative manufacturing processes that convert renewable feedstocks into intermediate and basic chemicals. Utilizing its proprietary biotechnology platform, the company engineers microorganisms to facilitate fermentation-based production, focusing on a pipeline of 20 key chemicals, including butanediol and butadiene. Genomatica has established itself as a leader in bioengineering, aiming to foster a transition to sustainable materials. Its technology has gained recognition for commercializing processes for butanediol, used in biodegradable plastics and apparel, and butylene glycol, which is important in cosmetics and personal care products. The company is also advancing research in bio-nylon. Genomatica's achievements have been acknowledged through several awards, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol. Founded in 1998 and headquartered in San Diego, California, Genomatica focuses on enhancing the economics, sustainability, and performance of chemical production.

Numab Therapeutics AG is a biotechnology company based in Wädenswil, Switzerland, founded in 2011. The company specializes in developing antibody-based therapeutics aimed at treating severe diseases, including cancer and chronic inflammation. Numab utilizes a unique plug-and-play platform that enhances the predictability of the drug discovery process, allowing for the efficient creation of multispecific biotherapeutics. Its research pipeline encompasses various therapeutic areas, including inflammatory bowel disease, immuno-oncology, autoimmunity, and inflammation.

Hummingbird Bioscience Pte. Ltd. is a biotechnology company based in Singapore, specializing in the development of antibody-based therapeutics for cancer. Founded in 2014, it leverages advances in systems biology and a proprietary rational antibody discovery platform to create innovative biotherapeutics. The company focuses on a diverse pipeline of drug candidates, which includes lead assets such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both aimed at addressing significant unmet medical needs in oncology. Hummingbird Bioscience has established strategic collaborations with notable organizations such as Cancer Research UK and Amgen, and it has received a product development grant from the Cancer Prevention and Research Institute of Texas. The company's goal is to enhance treatment options for patients facing challenging cancer diagnoses through its cutting-edge research and development efforts.

AMSilk GmbH, based in Munich, Germany, specializes in producing spider silk proteins and biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film used for protective coatings in medical devices, as well as biosteel spider silk fibers. AMSilk also develops over-the-counter wound care products like SanaSilk, designed to protect the skin, and provides spider silk-based solutions for surgical applications. Additionally, the company produces spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Its offerings include both raw materials and semi-finished products such as membranes and films. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company was founded in 2008.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, facilitating real-time online consultations. The platform also allows patients to order laboratory tests that can be conducted at home and helps them locate nearby hospitals and clinics. Additionally, HaloDoc provides access to licensed medical laboratory services and a medical delivery service known as ApotikAntar, further enhancing the convenience and accessibility of healthcare for its users.

Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.

CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative immune oncology biopharmaceuticals. Founded in 2016, the company specializes in a bispecific antibody platform designed to engage gamma-delta T cells, which play a crucial role in the immune response against cancer. Lava Therapeutics aims to create next-generation bispecific antibodies that not only activate and recruit the immune system but also enhance its ability to identify and eliminate tumor cells. The company's approach seeks to provide effective, safe, and cost-efficient treatments for both hematological and solid cancers, empowering healthcare professionals to better harness the body's immune capabilities in the fight against cancer.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

Mission Bio, Inc. specializes in tools for studying cellular heterogeneity in human health and life science research. The company utilizes microfluidic droplet technology to provide solutions for molecular analysis at the single-cell level. Its flagship product, the Tapestri Platform, is the first single-cell multi-omics platform, allowing for the simultaneous detection of genotype and phenotype from the same cell, which enhances the understanding of disease progression and treatment responses. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating targeted single-cell DNA custom panels, applicable in various fields including oncology, blood cancers, solid tumors, and genome editing validation. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders associated with neuronal imbalance. The company's lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator currently undergoing Phase IIa clinical trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective small molecule inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a persistent sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, as well as PRAX-222, an antisense oligonucleotide targeting SCN2A epilepsy, and a program for KCNT1 GOF epilepsy. The company engages in collaborations and licensing agreements with various partners, including RogCon Inc., Purdue Neuroscience Company, and Ionis Pharmaceuticals. Founded in 2015, Praxis Precision Medicines is headquartered in Cambridge, Massachusetts.

Bolt Biotherapeutics is a biotechnology company focused on developing innovative cancer treatments through its Boltbody platform, which centers on immune-stimulating antibody conjugates (ISAC). This platform combines tumor-targeting antibodies with potent immune stimulants, such as TLR agonists, to transform cold tumors into immunologically active ones and facilitate tumor elimination. One of the company's key developments is BDC-1001, designed as a monotherapy for patients with HER2-expressing solid tumors. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics aims to advance cancer immunotherapy and improve patient outcomes. The company was previously known as Bolt Therapeutics before rebranding in July 2015.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.

Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.

Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.

Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.

VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.

Unchained Labs is a developer of life science biologics tools designed to help researchers break free from tools that just don't cut it. It offers a multiplex protein stability platform for biologics that measures a host of protein stability parameters. The company's products include protein sizing systems, stability quantifiers, benchtop workflow solutions, automated buffer exchanges, concentration liberators, particle identifiers, and more, enabling biologics researchers to speed up their work with ease. Unchained Labs was established in 2013 and is based in Pleasanton, California, USA.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-release formulation of dexamethasone currently in Phase III trials for Ménière's disease, and OTO-313, which targets tinnitus and is in Phase I/II trials. Additionally, OTO-413 aims to treat cochlear synaptopathy and related hearing difficulties, while OTO-510 seeks to prevent hearing loss from cisplatin treatment. Another candidate, OTO-6XX, focuses on hair cell regeneration for severe hearing loss. Founded in 2008, Otonomy collaborates with various institutions and companies to enhance its research and development efforts in localized drug delivery for otologic disorders.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Archimedes Pharma Limited is a specialty pharmaceutical company based in Reading, United Kingdom, established in 2004. The company focuses on developing and providing products aimed at addressing the needs of patients with serious medical conditions, particularly cancer and addiction. Its product portfolio includes Gliadel, a treatment for high-grade gliomas; Zomorph, an oral sustained release morphine for managing cancer pain; Nozinan, which mitigates nausea and vomiting in cancer patients; and Pabrinex, a formulation of vitamins B and C designed for alcoholics undergoing acute withdrawal. Additionally, Archimedes Pharma offers Nasalfent, an intranasal fentanyl product for pain relief in cancer patients. The company operates primarily in the United Kingdom, France, and Germany.

ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.

Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.

BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.

Arakis Limited is engaged in the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The company specializes in understanding cytokine and receptor-mediated mechanisms of disease, which informs its research and development efforts. Arakis identifies and commercializes product opportunities by exploring new clinical applications for established drugs and drug templates, as well as enhancing the performance of existing medicines. Through its innovative approach, Arakis aims to address unmet medical needs in the therapeutic areas of inflammatory disease and pain.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California